Skip Nav Destination
Issues
1 December 2024
-
Cover Image
Cover Image
Therapeutic resistance is a persistent challenge in tubo-ovarian high-grade serous carcinoma (HGSC). Euchromatic histone-lysine N-methyltransferase 1/2 (EHMT1/2) promotes therapeutic resistance, rendering it a potentially promising therapeutic target for HGSC. In their study on page 1117, Nguyen and colleagues used a poly(ADP-ribose) polymerase (PARP) inhibitor-resistant HGSC mouse model to demonstrate the enhaced efficacy of combination EHMT1/2 and PARP inhibition. The dual treatment induced transposable element and doublestranded RNA (dsRNA) expression, facilitating interferon signaling and immune-stimulatory cytokine expression. Accordingly, increased combination treatment effectiveness was CD8+ T-cell–dependent. The cover features an immunofluorescent image of PARP inhibitor-resistant HGSC cells treated with pharmacologic PARP and EHMT1/2 inhibitors, where dsRNAs are magenta and nuclei are blue. This study is also Highlighted on page 1073. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1541-7786
EISSN 1557-3125
Molecular Cancer Research
Table of Contents
Highlights
Cancer Genes and Networks
Ruthenium Drug BOLD-100 Regulates BRAFMT Colorectal Cancer Cell Apoptosis through AhR/ROS/ATR Signaling Axis Modulation
Daryl Griffin; Robbie Carson; Debbie Moss; Tamas Sessler; Deborah Lavin; Vijay K. Tiwari; Shivaali Karelia; Richard Kennedy; Kienan I. Savage; Simon McDade; Adam Carie; Jim Pankovich; Mark Bazett; Sandra Van Schaeybroeck
Tumor Microenvironment and Immunobiology
EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent Manner
Lily L. Nguyen; Zachary L. Watson; Raquel Ortega; Elizabeth R. Woodruff; Kimberly R. Jordan; Ritsuko Iwanaga; Tomomi M. Yamamoto; Courtney A. Bailey; Francis To; Shujian Lin; Fabian R. Villagomez; Abigail D. Jeong; Saketh R. Guntupalli; Kian Behbakht; Veronica Gibaja; Nausica Arnoult; Edward B. Chuong; Benjamin G. Bitler
RNA Biology
Journal Archive
Molecular Cancer Research
(2002-Present; volumes 1-current)Published monthly since November, 2002.
(ISSN 0008-5472)
Cell Growth & Differentiation
(1990-2002; volumes 1-13)Published monthly 1990- September, 2002.
(ISSN 1044-9523)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.